These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 8813913)
1. Conservative management of stage T2 or T3a bladder cancer with deep transurethral resection followed by four cycles of chemotherapy. Uygur MC; Yaman I; Altug U; Erol D Br J Urol; 1996 Aug; 78(2):201-4. PubMed ID: 8813913 [TBL] [Abstract][Full Text] [Related]
2. Bladder preservation multimodality therapy as an alternative to radical cystectomy for treatment of muscle invasive bladder cancer. Maarouf AM; Khalil S; Salem EA; ElAdl M; Nawar N; Zaiton F BJU Int; 2011 May; 107(10):1605-10. PubMed ID: 20825396 [TBL] [Abstract][Full Text] [Related]
3. RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Hagan MP; Winter KA; Kaufman DS; Wajsman Z; Zietman AL; Heney NM; Toonkel LM; Jones CU; Roberts JD; Shipley WU Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):665-72. PubMed ID: 14529770 [TBL] [Abstract][Full Text] [Related]
4. Primary cisplatin, methotrexate and vinblastine chemotherapy with selective bladder preservation for muscle invasive carcinoma of the bladder: long-term followup of a prospective study. de la Rosa F; Garcia-Carbonero R; Passas J; Rosino A; Lianes P; Paz-Ares L J Urol; 2002 Jun; 167(6):2413-8. PubMed ID: 11992048 [TBL] [Abstract][Full Text] [Related]
5. Radical transurethral resection and chemotherapy in the treatment of muscle-invasive bladder cancer: a long-term follow-up. Thomas DJ; Roberts JT; Hall RR; Reading J BJU Int; 1999 Mar; 83(4):432-7. PubMed ID: 10210567 [TBL] [Abstract][Full Text] [Related]
6. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy. George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577 [TBL] [Abstract][Full Text] [Related]
7. [Conservative treatment with chemotherapy and radiotherapy in bladder cancer invading the muscle: preliminary results of a prospective study]. Zapatero A; Pinar B; Arellano R; López M; Marín A; Jiménez U; Pérez Torrubia A Arch Esp Urol; 1997 Jun; 50(5):448-54; discussion 454-6. PubMed ID: 9382586 [TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemotherapy (MVAC) in locally invasive bladder cancer. Sagaster P; Flamm J; Flamm M; Mayer A; Donner G; Oberleitner S; Havelec L; Lepsinger L; Ludwig H Eur J Cancer; 1996 Jul; 32A(8):1320-4. PubMed ID: 8869093 [TBL] [Abstract][Full Text] [Related]
9. Invasive bladder carcinoma: preliminary report of selective bladder conservation by transurethral surgery, upfront MCV (methotrexate, cisplatin, and vinblastine) chemotherapy and pelvic irradiation plus cisplatin. Marks LB; Kaufman SD; Prout GR; Heney NM; Griffin PP; Shipley WU Int J Radiat Oncol Biol Phys; 1988 Oct; 15(4):877-83. PubMed ID: 3182328 [TBL] [Abstract][Full Text] [Related]
10. Combined chemotherapy and radiation with selective organ preservation for muscle-invasive bladder carcinoma. A single-institution phase II study. Fellin G; Graffer U; Bolner A; Ambrosini G; Caffo O; Luciani L Br J Urol; 1997 Jul; 80(1):44-9. PubMed ID: 9240179 [TBL] [Abstract][Full Text] [Related]
11. Primary cisplatin, methotrexate and vinblastine aiming at bladder preservation in invasive bladder cancer: multivariate analysis on prognostic factors. Angulo JC; Sanchez-Chapado M; Lopez JI; Flores N J Urol; 1996 Jun; 155(6):1897-902. PubMed ID: 8618282 [TBL] [Abstract][Full Text] [Related]